HIV DART and Emerging Viruses: Frontiers in Drug Development and Antiretroviral Therapies

HIV DART 和新兴病毒：药物开发和抗逆转录病毒疗法的前沿

• 批准号: 10515647
• 负责人: Raymond Felix Schinazi
• 金额: $ 2万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-11-13 至 2023-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10515647
• 关键词: Accreditation; Acquired Immunodeficiency Syndrome; Adherence; Applications Grants; Area; Biology; Chemistry; Chikungunya fever; Childhood; Chronic; Clinical; Clinical Research; Communicable Diseases; Communities; Dengue Fever; Development; Disease; Disease remission; Drug Kinetics; Ebola; Education; Educational workshop; Elderly; Ensure; Face; Formulation; Future; HIV; HIV Infections; HIV/AIDS; Health Personnel; Health Professional; Health Services Accessibility; Hepatitis B; Hepatitis C virus; Individual; Inflammation; International; Knowledge; Learning; Location; Medical; Methods; Nurses; Oral; Pharmaceutical Preparations; Pharmacology; Physicians; Population; Postdoctoral Fellow; Research Personnel; Retroviridae; Role; Scholarship; Scientist; Serology; System; Therapeutic; Therapeutic Agents; Time; Training; Treatment Protocols; United States; United States National Institutes of Health; Viral; Viral reservoir; Virus; Yellow Fever; antiretroviral therapy; antiviral drug development; co-infection; continuing medical education; design; drug development; drug metabolism; frontier; graduate student; improved; lectures; microbicide; neuroAIDS; novel; novel therapeutics; posters; programs; side effect; symposium; treatment as prevention; vaccine development; zika fever

Abstract/Project Summary Thanks to advances in antiretroviral therapy, the face of HIV and AIDS has been gradually and meaningfully transformed from a deadly disease, into a chronic condition that is managed with careful adherence to life-long treatment regimens. The need for improved drugs, with fewer side-effects, improved adherence and more favorable pharmacokinetics increases as the number of infected individuals on long-term therapy continues to rise. Importantly, the quest for an HIV cure continues to gain momentum as we learn more about viral reservoirs and mechanisms of viral persistence. HIV DART and Emerging Viruses is a biennial conference for physicians, clinicians, nurses, scientists and clinical researchers that will focus on the latest discoveries in these areas. Specific Aims: 1. Gather cross-disciplinary professionals such as clinicians, health care workers, researchers and basic scientists together in an interactive workshop setting to share and discuss the latest developments in the field of HIV and emerging viruses; 2. Facilitate the neutral and balanced exchange of scientific knowledge with regard to antiviral drug development, vaccine development, and recent progress in curative strategies; 3. Enhance the training of young scientists such as graduate students and post-doctoral fellows and provide increased opportunities for underrepresented scientists and health care workers through attendee scholarships. Educational Objectives: 1. Identify novel therapeutic agents and viral targets for HIV, retroviruses and other emerging viruses; 2. Understand HIV reservoirs and viral persistence; 3. Discuss novel remission, cure, and eradication strategies for HIV; 4. Discuss inflammation in the context of HIV infection, neuroAIDS and AIDS in geriatric and pediatric populations; 5. Understand drug metabolism and pharmacology and discuss improved formulations; 6. Discuss treatment access, treatment as prevention and the role of microbicides; 7. Discuss HIV treatment in the context of co-infection with Hepatitis B or hepatitis C virus; 8. Discuss recent advances in vaccine development and systems serology; 9. Discuss recent scientific discoveries with regard to emerging viral threats such as Ebola, Zika, chikungunya, dengue and yellow fever. Design & Methods: HIV DART and Emerging Viruses will take place in the United States of America over a 2.5 days period, at a location that is easily accessed by both national and international delegates. The program will include plenary lectures, oral abstract presentations, discussion panels and a debate. This ACCME-accredited program will provide ample time for formal and informal networking and discussion amongst the delegates during the poster session and meal breaks.

摘要/项目摘要 多亏了抗逆转录病毒疗法的进步，艾滋病毒和艾滋病的面孔逐渐发展 并有意义地从致命疾病转变为慢性病 仔细遵守终身治疗方案。需要改善药物的需求，更少 随着数量的增加，副作用，提高的依从性和更有利的药代动力学会增加 在长期治疗中受感染的个体的中断持续上升。重要的是，寻求艾滋病毒 当我们进一步了解有关病毒储存库和机制的更多信息时，CURE继续获得动力 病毒持久性。艾滋病毒和新兴病毒是一次医师两年一的会议， 临床医生，护士，科学家和临床研究人员将重点介绍 这些区域。 具体目的：1。收集跨学科专业人员，例如临床医生，医疗保健 工人，研究人员和基础科学家一起在交互式研讨会上共享 并讨论艾滋病毒和新兴病毒领域的最新发展； 2。促进 关于抗病毒药的中立和平衡的科学知识交换 开发，疫苗开发以及治疗策略的最新进展； 3。增强 培训年轻科学家，例如研究生和博士后研究员，并提供 通过代表性不足的科学家和卫生保健工作者增加了机会 与会者奖学金。教育目标：1。确定新颖的治疗剂和病毒 HIV，逆转录病毒和其他新兴病毒的靶标； 2。了解艾滋病毒水库和病毒 持久3。讨论艾滋病毒的新型缓解，治愈和消除策略； 4。讨论 在艾滋病毒感染，神经辅助和老年病毒的炎症中炎症 人口； 5。了解药物代谢和药理学并讨论改善 配方； 6。讨论治疗获取，治疗作为预防和生液的作用； 7。在与乙型肝炎或丙型肝炎病毒共同感染的背景下讨论HIV治疗； 8。 讨论疫苗开发和系统血清学的最新进展； 9。讨论最近 关于新兴病毒威胁的科学发现，例如埃博拉病毒，Zika，Chikungunya， 登革热和黄热病。设计与方法：HIV飞镖和新兴病毒将发生 美利坚合众国在2.5天内 国家和国际代表。该计划将包括全体讲座，口头摘要 演讲，讨论小组和辩论。该ACCME认可的计划将提供 充足的时间进行正式和非正式的网络以及在代表之间 海报会议和用餐休息。